Completed × Burkitt Lymphoma × Rituximab × Clear all
NCT00080886 2023-10-06

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

University of Nebraska

Phase 2 Completed
68 enrolled
NCT00726700 2021-07-07

Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

Universität des Saarlandes

Phase 2 Completed
109 enrolled
NCT00052936 2021-05-18

Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Universität des Saarlandes

Phase 3 Completed
1,506 enrolled
NCT00003963 2020-08-03

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation

Jonsson Comprehensive Cancer Center

Phase 2 Completed
14 enrolled
NCT00392691 2019-05-15

Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Swiss Cancer Institute

Phase 1 Completed
20 enrolled
NCT00119392 2018-06-29

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Completed
42 enrolled 11 charts
NCT00867529 2018-01-02

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Completed
63 enrolled 12 charts
NCT00691015 2017-06-28

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
48 enrolled 12 charts
NCT00601718 2017-05-25

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

University of Washington

Phase 1/2 Completed
29 enrolled 10 charts
NCT00005601 2016-12-07

Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Completed
58 enrolled
NCT00054639 2014-05-28

Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
48 enrolled 5 charts
NCT00062296 2013-07-11

Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Fox Chase Cancer Center

Phase 2 Completed
5 enrolled
NCT00058292 2012-06-01

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Northwestern University

Phase 1 Completed
44 enrolled
NCT00080925 2012-03-08

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
20 enrolled